Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 28, 2014. The report serves to disclose the publication of final terms for a new debt issuance by GlaxoSmithKline Capital plc, a subsidiary of GSK.
Key Financial Metrics
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The document focuses exclusively on capital market activity.
- New Debt Issuance: EUR 1,500,000,000 in 0.625% Notes due 2019.
- New Debt Issuance: EUR 1,000,000,000 in 1.375% Notes due 2024.
- Guarantee: Both note issuances are guaranteed by GlaxoSmithKline plc.
- Programme: Issued under the £15,000,000,000 Euro Medium Term Note Programme.
Material Changes
The filing does not report material changes to the company's business operations, financial performance, or prior period comparisons. The primary change disclosed is the expansion of the company's debt portfolio through the new note issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard risk disclosure regarding the distribution of the Final Terms and Base Prospectus, noting that the information is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions.
Investor Verification Checklist
- Verify the availability of the Final Terms and Base Prospectus via the National Storage Mechanism (NSM) or Morningstar.
- Confirm the specific jurisdictions where the notes are offered as per the Base Prospectus.
- Review the full terms of the guarantee provided by GlaxoSmithKline plc for the subsidiary's notes.
- Check subsequent filings for the impact of this EUR 2.5 billion issuance on the company's total debt load and interest coverage.